| 股票 | 标签 | 富途行业 | PE | PB | 股息率 | 分红率 | 毛利率 | ROE | 固定资产 | 负债率 | OCF/市值 | 营收增速 | 利润增速 | 近60日 | YTD | 近一年 | 距52周高 | 市值亿 ▾ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 恒瑞医药 01276 | 中性 | 药品 | 34.7 | 4.16 | 0.5% | 17% | 86% | 15% | 13% | 12% | 3.3% | +18% | +27% | -14% | -34% | -36% | 49% | 3086 |
| 翰森制药 03692 | 成长兑现 | 药品 | 28.6 | 5.05 | 1.2% | 34% | 90% | 18% | 8% | 11% | 1.6% | +28% | +33% | +24% | +1% | +3% | 82% | 2198 |
| 信达生物 01801 | 纯久期 | 药品 | 125.8 | 7.48 | 0.0% | 0% | 86% | 5% | 18% | 48% | 6.0% | +45% | +999% | +38% | +34% | +13% | 91% | 1786 |
| 石药集团 01093 | 中性 | 药品 | 13.1 | 2.58 | 3.0% | 39% | 66% | 12% | 26% | 26% | 2.7% | -6% | -7% | +36% | +17% | +6% | 85% | 1116 |
| 中国生物制药 01177 | 轻资产现金牛 | 药品 | 37.7 | 2.76 | 2.2% | 82% | 82% | 8% | 12% | 45% | 6.6% | +15% | -13% | +26% | -9% | -27% | 62% | 1034 |
| 康龙化成 03759 | 中性 | 药品 | 27.0 | 2.83 | 0.8% | 21% | 34% | 12% | 45% | 42% | 3.8% | +20% | -5% | +93% | +50% | +43% | 83% | 532 |
| 凯莱英 06821 | 中性 | 药品 | 40.5 | 2.36 | 1.1% | 45% | 42% | 7% | 31% | 13% | 1.7% | +20% | +26% | +50% | +92% | +56% | 96% | 483 |
| 复星医药 02196 | 中性 | 药品 | 11.0 | 0.77 | 2.8% | 31% | 50% | 7% | 19% | 48% | 8.0% | +6% | +26% | +2% | -15% | -23% | 57% | 431 |
| 三生制药 01530 | 定价权·品牌 | 药品 | 4.3 | 1.29 | 1.5% | 7% | 92% | 40% | 16% | 16% | 23.6% | +103% | +329% | +0% | -32% | -41% | 44% | 411 |
| 先声药业 02096 | 定价权·品牌 | 药品 | 16.5 | 2.75 | 1.8% | 29% | 82% | 16% | 18% | 36% | 4.3% | +22% | +95% | +21% | -1% | -11% | 82% | 299 |
| 英矽智能 03696 | 亏损或困境 | 药品 | -12.2 | 6.62 | 0.0% | — | 82% | 0% | 2% | 8% | 1.1% | -34% | -1965% | +47% | +31% | +103% | 60% | 284 |
| 华润医药 03320 | 中性 | 药品 | 5.8 | 0.46 | 4.9% | 29% | 16% | 8% | 9% | 59% | 75.7% | +9% | +20% | -7% | +3% | -5% | 69% | 279 |
| 康哲药业 00867 | 现金流红利 | 药品 | 15.2 | 1.30 | 3.1% | 47% | 72% | 9% | 2% | 9% | 3.8% | +15% | -6% | +3% | -12% | -11% | 72% | 269 |
| 东阳光药 06887 | 亏损或困境 | 药品 | -65.6 | 4.84 | 0.0% | — | 76% | 12% | 32% | 64% | 5.9% | +25% | +1038% | +10% | -18% | -26% | 67% | 215 |
| 和黄医药 00013 | 纯久期 | 药品 | 140.0 | 1.99 | 0.0% | 0% | 39% | 46% | 6% | 29% | 0.8% | -13% | +1101% | +31% | +9% | -4% | 78% | 197 |
| 丽珠医药 01513 | 现金流红利 | 药品 | 9.4 | 1.18 | 8.1% | 76% | 66% | 15% | 17% | 35% | 20.4% | +6% | +9% | -18% | -24% | -40% | 55% | 181 |
| 远大医药 00512 | 现金流红利 | 药品 | 15.7 | 1.01 | 3.4% | 54% | 55% | 7% | 16% | 37% | 9.0% | +6% | -50% | -0% | -36% | -45% | 52% | 174 |
| 联邦制药 03933 | 现金流红利 | 药品 | 26.5 | 0.83 | 5.7% | 150% | 42% | 13% | 36% | 43% | 12.0% | +0% | -18% | +2% | -26% | -42% | 48% | 165 |
| 海西新药 02637 | 中性 | 药品 | 90.7 | 8.16 | 0.0% | 0% | 83% | 17% | 22% | 14% | 0.0% | +30% | +36% | +10% | +46% | +131% | 66% | 157 |
| 康臣药业 01681 | 定价权·品牌 | 药品 | 8.4 | 2.08 | 3.0% | 25% | 78% | 25% | 13% | 24% | 7.1% | +20% | +24% | -2% | -11% | +1% | 71% | 114 |
| 劲方医药-B 02595 | 亏损或困境 | 药品 | -7.0 | 5.71 | 0.0% | — | 64% | 0% | 1% | 17% | -0.9% | +30% | -177% | -4% | +16% | +35% | 52% | 106 |
| 礼邦医药-B 09637 | 亏损或困境 | 药品 | -12.4 | 6.19 | 0.0% | — | 44% | 0% | 49% | 62% | -1.7% | +390% | -134% | +27% | +27% | +27% | 62% | 100 |
| 丹诺医药-B 06872 | 亏损或困境 | 药品 | -54.8 | 11.66 | 0.0% | — | — | 0% | — | 32% | -1.4% | +0% | -10% | -27% | +122% | +122% | 58% | 88 |
| 石四药集团 02005 | 中性 | 药品 | 15.5 | 1.01 | 3.0% | 46% | 42% | 6% | 43% | 40% | 6.0% | -28% | -55% | +19% | -2% | -1% | 84% | 79 |
| 绿叶制药 02186 | 中性 | 药品 | 9.4 | 0.43 | 0.0% | 0% | 66% | 4% | 16% | 44% | 0.4% | +9% | +14% | +0% | -31% | -43% | 48% | 76 |
| 四环医药 00460 | 成长兑现 | 药品 | 20.7 | 1.01 | 2.8% | 58% | 69% | 4% | 18% | 41% | 1.1% | +44% | +141% | -14% | -36% | -45% | 41% | 72 |
| 海普瑞 09989 | 现金流红利 | 药品 | 26.6 | 0.45 | 3.9% | 104% | 31% | 3% | 15% | 27% | 12.2% | +8% | -43% | +6% | -16% | -29% | 71% | 62 |
| 江西生物 06915 | 中性 | 药品 | 66.0 | 5.66 | 0.0% | 0% | 77% | 21% | 39% | 11% | 1.3% | +12% | +32% | +59% | +59% | +59% | 84% | 55 |
| 宝济药业-B 02659 | 亏损或困境 | 药品 | -12.3 | 3.11 | 0.0% | — | 89% | -31% | 36% | 28% | -1.6% | +734% | -13% | -16% | -79% | -39% | 8% | 52 |
| 中国同辐 01763 | 中性 | 药品 | 13.1 | 0.80 | 2.3% | 30% | 50% | 6% | 29% | 48% | 17.8% | -1% | -21% | -10% | -23% | -7% | 62% | 49 |
| 长风药业 02652 | 亏损或困境 | 药品 | -611.1 | 3.08 | 0.0% | — | 76% | 0% | 36% | 17% | -2.5% | -26% | -88% | -41% | -69% | -25% | 22% | 48 |
| 山东新华制药股份 00719 | 重资产陷阱 | 药品 | 15.9 | 0.65 | 3.1% | 49% | 19% | 6% | 40% | 41% | 8.6% | +8% | -34% | +2% | -12% | -24% | 74% | 39 |
| 泰德医药 03880 | 成长兑现 | 药品 | 15.6 | 1.61 | 0.0% | 0% | 63% | 23% | 22% | 13% | 3.2% | +35% | +284% | +4% | -30% | -43% | 60% | 30 |
| 德琪医药-B 06996 | 中性 | 药品 | 39.1 | 2.29 | 0.0% | 0% | 84% | -32% | 14% | 49% | -1.8% | +20% | +22% | +3% | -6% | -35% | 44% | 24 |
| 艾美疫苗 06660 | 亏损或困境 | 药品 | -3.0 | 0.75 | 0.0% | — | 65% | -22% | 45% | 55% | 8.0% | -5% | -179% | -4% | -42% | -64% | 36% | 23 |
| 雅各臣科研制药 02633 | 中性 | 药品 | 7.0 | 0.91 | 4.1% | 29% | 43% | 13% | 42% | 34% | 15.6% | -0% | +0% | -4% | -19% | -26% | 71% | 21 |
| 君圣泰医药-B 02511 | 亏损或困境 | 药品 | -6.6 | 10.73 | 0.0% | — | — | -68% | — | 34% | -2.6% | +0% | +36% | +19% | +4% | -9% | 65% | 21 |
| 金嗓子 06896 | 定价权·品牌 | 药品 | 6.8 | 1.22 | 14.9% | 102% | 76% | 18% | 19% | 40% | 6.3% | -17% | -18% | -28% | -16% | -31% | 66% | 17 |
| 东瑞制药 02348 | 中性 | 药品 | 5.5 | 0.38 | 6.4% | 35% | 50% | 6% | 26% | 16% | 11.7% | +21% | -61% | -5% | -16% | -15% | 81% | 15 |
| 兆科眼科-B 06622 | 亏损或困境 | 药品 | -5.6 | 0.87 | 0.0% | — | 50% | -12% | 8% | 19% | -9.1% | -52% | +8% | -8% | -14% | -33% | 59% | 14 |
| 九源基因 02566 | 中性 | 药品 | 7.9 | 0.65 | 1.3% | 10% | 81% | 9% | 17% | 22% | 21.4% | -0% | +4% | +2% | -30% | -58% | 35% | 13 |
| 亿胜生物科技 01061 | 轻资产现金牛 | 药品 | 4.7 | 0.49 | 5.4% | 26% | 89% | 14% | 14% | 31% | 22.7% | +9% | +4% | -16% | -40% | -56% | 40% | 12 |
| 开拓药业-B 09939 | 亏损或困境 | 药品 | -4.1 | 7.22 | 0.0% | — | 25% | -85% | 37% | 46% | -12.4% | +583% | -35% | -24% | -7% | -18% | 39% | 9 |
| 白花油 00239 | 现金流红利 | 药品 | 7.9 | 1.06 | 7.6% | 60% | 86% | 13% | 28% | 13% | 5.9% | -10% | +16% | +8% | +11% | +13% | 92% | 8 |
| 泰凌医药 01011 | 亏损或困境 | 药品 | -23.3 | -5.92 | 0.0% | — | 40% | 0% | 0% | 179% | 2.0% | -34% | +49% | -9% | -49% | -44% | 31% | 8 |
| 李氏大药厂 00950 | 轻资产现金牛 | 药品 | 6.1 | 0.34 | 3.7% | 22% | 51% | 5% | 13% | 45% | 52.9% | +3% | -26% | +13% | -18% | -29% | 46% | 7 |
| 中智药业 03737 | 中性 | 药品 | 32.2 | 0.50 | 0.0% | 0% | 54% | 2% | 30% | 40% | 10.1% | -18% | -81% | +7% | +32% | -8% | 76% | 6 |
| 联康生物科技集团 00690 | 定价权·品牌 | 药品 | 7.5 | 0.80 | 5.0% | 38% | 83% | 25% | 26% | 29% | 11.7% | +6% | +13% | -29% | -46% | -59% | 37% | 4 |
| 兴科蓉医药 06833 | 中性 | 药品 | 9.4 | 0.39 | 1.3% | 12% | 11% | 5% | 15% | 62% | 75.9% | -23% | -13% | -14% | -9% | -34% | 64% | 3 |
| 励晶太平洋 00575 | 亏损或困境 | 药品 | -16.3 | -5.21 | 0.0% | — | — | 0% | 2% | 1263% | -6.6% | -55% | -5% | +47% | -21% | +2% | 70% | 2 |
| 精优药业 00858 | 亏损或困境 | 药品 | -0.2 | 0.61 | 0.0% | — | 44% | -115% | 11% | 36% | 0.1% | -7% | -538% | +16% | -4% | -32% | 58% | 2 |
| 天大药业 00455 | 亏损或困境 | 药品 | -3.2 | 0.50 | 0.0% | — | 41% | -14% | 46% | 39% | -4.7% | -2% | -14% | +12% | -21% | -43% | 57% | 2 |
| 华控康泰 01312 | 亏损或困境 | 药品 | -0.9 | 0.37 | 0.0% | — | 56% | -56% | 17% | 55% | 12.5% | +2% | -387% | +54% | +17% | +17% | 71% | 2 |
| 培力农本方 01498 | 亏损或困境 | 药品 | -5.2 | 1.16 | 0.0% | — | 54% | -29% | 38% | 81% | -3.3% | -12% | +1% | -10% | -24% | -40% | 59% | 1 |
| 三爱健康集团 01889 | 亏损或困境 | 药品 | -1.3 | 0.15 | 0.0% | — | 17% | -7% | 13% | 23% | -184.7% | +5% | -916% | -29% | -62% | -57% | 29% | 0 |
点表头排序。市值单位亿港元;财务为最近年报(futu 筛选器);分红率 = 股息率 × PE;OCF/市值 = 经营现金流 ÷ 市值(无 FCF);距52周高 = 现价 / 52 周最高。